<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29115505</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-3004</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Molecular medicine reports</Title><ISOAbbreviation>Mol Med Rep</ISOAbbreviation></Journal><ArticleTitle>Alanine scanning mutagenesis of SP70 epitope in characterizing species&#x2011;specific antibodies induced by enterovirus 71&#x2011;based antigens.</ArticleTitle><Pagination><StartPage>1006</StartPage><EndPage>1014</EndPage><MedlinePgn>1006-1014</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3892/mmr.2017.7992</ELocationID><Abstract><AbstractText>The enterovirus 71 (EV71) SP70 epitope, derived from amino acids 208&#x2011;222 of VP1, is a neutralizing epitope. The present study aimed to assess the inter&#x2011;species differences of the antibodies induced by EV71&#x2011;based antigens in responses to SP70 mutant peptides. BALB/c mice and Lou/C rats were immunized with EV71 SP70. Monoclonal antibodies (Mabs) were produced by hybridoma clones. Serum polyclonal antibodies (Pabs) were produced from BALB/c mice and New Zealand white rabbits immunized with recombinant EV71 VP1 (rEV71&#x2011;VP1) protein or inactivated EV71. Micro&#x2011;neutralization and immunofluorescence assays were used to evaluate the capacity of the antibodies to bind to EV71. Reactivity of Mabs and Pabs to mutated SP70 were determined by alanine scanning mutagenesis. Furthermore, serums from EV71&#x2011;infected patients were collected to examine the affinity of SP70 antibody in the serum to mutated SP70, using competitive ELISA. The binding affinity of mouse Mabs to the SP70 epitope was increased by alanine substitution at sites of 210, 212, 213, 214, and 221. The binding affinity of rat Mabs to the SP70 epitope was increased by alanine substitution at sites 210, 217, 219, and 221. Mouse serum Pabs elicited by inactivated EV71 bound wild&#x2011;type SP70, but lost affinity for mutated peptides. Conversely, rabbit serum Pabs elicited by inactivated EV71 robustly recognized SP70 mutants. Mouse serum Pabs elicited by rEV71&#x2011;VP1 presented the same trend as mouse Mabs. Mutations at sites 214, 215, and 217 led to loss of recognition by rabbit Pabs elicited by rEV71&#x2011;VP1, while most mutations did not influence antibody binding. Compared with the wild&#x2011;type, mutations at the sites 209, 219 and 221 of SP70 lead to increased affinity with the serum antibodies produced by the EV71&#x2011;infected patients. Antibody responses triggered by inactivated EV71, rEV71&#x2011;VP1 and EV71 SP70 differed among species in neutralizing capacity and affinity for SP70 mutant peptides.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Vaccine R&amp;D, Institute of Virology, Zhejiang Academy of Medical Science, Hangzhou, Zhejiang 310053, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Vaccine R&amp;D, Institute of Virology, Zhejiang Academy of Medical Science, Hangzhou, Zhejiang 310053, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Vaccine R&amp;D, Institute of Virology, Zhejiang Academy of Medical Science, Hangzhou, Zhejiang 310053, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Limei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Vaccine R&amp;D, Institute of Virology, Zhejiang Academy of Medical Science, Hangzhou, Zhejiang 310053, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yunshui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Vaccine R&amp;D, Institute of Virology, Zhejiang Academy of Medical Science, Hangzhou, Zhejiang 310053, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yongneng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Vaccine R&amp;D, Institute of Virology, Zhejiang Academy of Medical Science, Hangzhou, Zhejiang 310053, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Fangchang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Vaccine R&amp;D, Institute of Virology, Zhejiang Academy of Medical Science, Hangzhou, Zhejiang 310053, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Zian</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Vaccine R&amp;D, Institute of Virology, Zhejiang Academy of Medical Science, Hangzhou, Zhejiang 310053, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Jiangsen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Zhejiang Provincial Key Laboratory of Vaccine R&amp;D, Institute of Virology, Zhejiang Academy of Medical Science, Hangzhou, Zhejiang 310053, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Mol Med Rep</MedlineTA><NlmUniqueID>101475259</NlmUniqueID><ISSNLinking>1791-2997</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>11</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29115505</ArticleId><ArticleId IdType="pmc">PMC5780067</ArticleId><ArticleId IdType="doi">10.3892/mmr.2017.7992</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sanders SA, Herrero LJ, McPhie K, Chow SS, Craig ME, Dwyer DE, Rawlinson W, McMinn PC. Molecular epidemiology of enterovirus 71 over two decades in an Australian urban community. Arch Virol. 2006;151:1003&#x2013;1013. doi: 10.1007/s00705-005-0684-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-005-0684-9</ArticleId><ArticleId IdType="pubmed">16369861</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Syoji M, Ueki Y, Sato Y, Okimura Y, Saito N, Kikuchi N, Yagi T, Numakura H. Isolation of enterovirus 71 from patients with hand, foot and mouth disease in a local epidemic on March 2006, in Miyagi prefecture, Japan. Jpn J Infect Dis. 2006;59:348.</Citation><ArticleIdList><ArticleId IdType="pubmed">17060708</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol. 2008;49:103&#x2013;112. doi: 10.1016/S1875-9572(08)60023-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1875-9572(08)60023-6</ArticleId><ArticleId IdType="pubmed">19054914</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee KK, Takebe Y, Kamarulzaman A. Emerging and re-emerging viruses in Malaysia, 1997&#x2013;2007. Int J Infect Dis. 2009;13:307&#x2013;318. doi: 10.1016/j.ijid.2008.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2008.09.005</ArticleId><ArticleId IdType="pmc">PMC7110734</ArticleId><ArticleId IdType="pubmed">19010076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY. Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet. 1998;352:1391. doi: 10.1016/S0140-6736(05)60789-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)60789-1</ArticleId><ArticleId IdType="pubmed">9802304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao LX, Wu B, Bao WX, Han FA, Xu L, Ge QJ, Yang J, Yuan ZH, Miao CH, Huang XX, et al. Epidemiology of hand, foot, and mouth disease and genotype characterization of enterovirus 71 in Jiangsu, China. J Clin Virol. 2010;49:100&#x2013;104. doi: 10.1016/j.jcv.2010.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2010.07.009</ArticleId><ArticleId IdType="pubmed">20719557</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, Ji F, Wang XJ, Gao YJ, Chen L, et al. An outbreak of hand, foot and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol. 2009;44:262&#x2013;267. doi: 10.1016/j.jcv.2009.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.02.002</ArticleId><ArticleId IdType="pubmed">19269888</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9:78&#x2013;85. doi: 10.3201/eid1301.020112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, Ning HC, Chung PW, Kang CM. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J. 1999;18:1092&#x2013;1096. doi: 10.1097/00006454-199912000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-199912000-00013</ArticleId><ArticleId IdType="pubmed">10608631</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC, Chen YJ, Yang YJ, Lin SJ, Yeh TF. Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis. 1999;29:184&#x2013;190. doi: 10.1086/520149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/520149</ArticleId><ArticleId IdType="pubmed">10433583</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z, Lu S. EV71: An emerging infectious disease vaccine target in the Far East? Vaccine. 2010;28:3516&#x2013;3521. doi: 10.1016/j.vaccine.2010.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.03.003</ArticleId><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res. 2007;125:61&#x2013;68. doi: 10.1016/j.virusres.2006.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Chang LY. Development of enterovirus 71 vaccines. Expert Rev Vaccines. 2010;9:149&#x2013;156. doi: 10.1586/erv.09.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.09.152</ArticleId><ArticleId IdType="pubmed">20109026</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995;39:195&#x2013;205. doi: 10.1016/0168-1702(95)00087-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1702(95)00087-9</ArticleId><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XF, Jia Q, Chow VT, Kwang J. Characterization of a novel monoclonal antibody reactive against the N-terminal region of enterovirus 71 VP1 capsid protein. J Virol Methods. 2013;188:76&#x2013;82. doi: 10.1016/j.jviromet.2012.11.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.11.038</ArticleId><ArticleId IdType="pubmed">23219932</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama WM. Production of monoclonal antibodies. Curr Protoc Cell Biol Chapter. 2001;16 doi: 10.1002/0471143030.cb1601s03. Unit 16 1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471143030.cb1601s03</ArticleId><ArticleId IdType="pubmed">18228333</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama WM, Christensen M, Dos Santos G, Miller D, Ho J, Wu T, Dziegelewski M, Neethling FA. Production of monoclonal antibodies. Curr Protoc Immunol. 2013;102 doi: 10.1002/0471142735.im0205s102. Unit 2.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471142735.im0205s102</ArticleId><ArticleId IdType="pubmed">24510488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich K, Juozapaitis M, Ranadheera C, Kessler U, Martin A, Eisel J, Beutling U, Frank R, Schwemmle M. Identification of high-affinity PB1-derived peptides with enhanced affinity to the PA protein of influenza A virus polymerase. Antimicrob Agents Chemother. 2011;55:696&#x2013;702. doi: 10.1128/AAC.01419-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01419-10</ArticleId><ArticleId IdType="pmc">PMC3028788</ArticleId><ArticleId IdType="pubmed">21135188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping J, Li C, Deng G, Jiang Y, Tian G, Zhang S, Bu Z, Chen H. Single-amino-acid mutation in the HA alters the recognition of H9N2 influenza virus by a monoclonal antibody. Biochem Biophys Res Commun. 2008;371:168&#x2013;171. doi: 10.1016/j.bbrc.2008.04.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2008.04.045</ArticleId><ArticleId IdType="pubmed">18424263</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha D, Lefebvre DJ, Ooms K, Huang L, Delputte PL, Van Doorsselaere J, Nauwynck HJ. Single amino acid mutations in the capsid switch the neutralization phenotype of porcine circovirus 2. J Gen Virol. 2012;93:1548&#x2013;1555. doi: 10.1099/vir.0.042085-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.042085-0</ArticleId><ArticleId IdType="pubmed">22492916</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, et al. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine. 2011;29:4362&#x2013;4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. Crystal structure of human enterovirus 71. Science. 2012;336:1274. doi: 10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>